Anika Enrolls First Patient in Supplemental Phase III CINGAL Trial

Anika Therapeutics enrolled the first patient in a supplemental Phase III trial evaluating CINGAL® hyaluronic acid/corticosteroid viscosupplement for the treatment of knee OA symptoms.

The supplemental trial will enroll patients at 30 European sites, randomized to receive CINGAL, MONOVISC® or a synthetic glucocorticoid for evaluation at 26...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us